GoodRx Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GoodRx Holdings, Inc. on December 22, 2023, reporting events that occurred on December 21, 2023. The filing addresses corporate governance changes, specifically the election of a new director and the adoption of a deferred compensation plan for directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel and governance matters.
Material Changes
- Director Election: The Board elected Kelly J. Kennedy as a Class I director, effective immediately, to fill an existing vacancy. Her term expires at the 2024 Annual Meeting of Stockholders.
- Committee Assignment: Ms. Kennedy was appointed to the Audit Committee. The Board determined she qualifies as an independent director and an audit committee financial expert.
- Compensation Grant: Ms. Kennedy received an initial award of restricted stock units (RSUs) with an aggregate target value of $420,000. The number of RSUs was calculated based on the 30-calendar day average closing price of Class A common stock prior to the grant date.
- Vesting Schedule: The initial RSU award vests in three equal tranches (one-third) on each of the first three anniversaries of the grant date, contingent on continued service.
- New Deferred Compensation Plan: The Board adopted a Deferred Compensation Plan for Directors effective January 1, 2024, allowing non-employee directors to defer cash retainers and RSU settlements into RSUs.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies related to operations were disclosed in this report. The filing notes that Ms. Kennedy is subject to standard indemnification and proprietary information agreements.
Key Facts for Investor Verification
- Verify the exact number of RSUs granted to Ms. Kennedy by checking the 30-day average stock price prior to December 21, 2023, against the $420,000 target value.
- Review the full text of the Deferred Compensation Plan for Directors, which will be filed in the upcoming Form 10-K for the fiscal year ending December 31, 2023.
- Confirm Ms. Kennedy's independence status and financial expertise qualifications as disclosed in the filing.
- Note that the press release regarding this election is attached as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.